Tag Archives: ABH

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

The past year brought the biotech sector a mixed bag of news. Some of it was positive – for instance, the FDA picked up its drug approval pace in 2011 and, in some cases, even surprised the most hardened biotech…


Can Other Cell Therapy Firms Avoid Dendreon’s Fate?

Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics. At the recent 2011 Stem Cell Meeting on the Mesa, panelists debated…